Monday, June 22, 2020 4:58:55 PM
FDA accepts Myovant application for relugolix for prostate cancer
The FDA accepts for review Myovant Sciences' (MYOV +2.8%) marketing application for relugolix for the treatment of advanced prostate cancer. The agency's action date is December 20.
On June 1, it filed a U.S. application for a relugolix combo pill for the treatment of women with heavy menstrual bleeding associated with uterine fibroids.
https://seekingalpha.com/news/3584919-fda-accepts-myovant-application-for-relugolix-for-prostate-cancer?v=1592837908
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM